Trial · NCT03150056
Results by group430
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 430
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 60 mg+Abiraterone 1000 mg | Any AEs | 10 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 60 mg Alternate+Abiraterone 1000 mg | Any AEs | 6 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 40 mg+Abiraterone 1000 mg | Any AEs | 4 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 80 mg+Enzalutamide 160 mg | Any AEs | 10 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 60 mg+Enzalutamide 160 mg | Any AEs | 22 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 60 mg Alternate+Enzalutamide 160 mg | Any AEs | 21 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 60 mg+Abiraterone 1000 mg | Any SAEs | 4 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 60 mg Alternate+Abiraterone 1000 mg | Any SAEs | 2 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 40 mg+Abiraterone 1000 mg | Any SAEs | 0 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 80 mg+Enzalutamide 160 mg | Any SAEs | 1 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 60 mg+Enzalutamide 160 mg | Any SAEs | 6 | Participants | |
| Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | GSK525762 60 mg Alternate+Enzalutamide 160 mg | Any SAEs | 7 | Participants | |
| Number of Participants With AEs Leading to Any Dose Reduction or Delays | GSK525762 60 mg+Abiraterone 1000 mg | Dose reduction | 4 | Participants | |
| Number of Participants With AEs Leading to Any Dose Reduction or Delays | GSK525762 60 mg Alternate+Abiraterone 1000 mg | Dose reduction | 1 | Participants | |
| Number of Participants With AEs Leading to Any Dose Reduction or Delays | GSK525762 40 mg+Abiraterone 1000 mg | Dose reduction | 0 | Participants | |
| Number of Participants With AEs Leading to Any Dose Reduction or Delays | GSK525762 80 mg+Enzalutamide 160 mg | Dose reduction | 7 | Participants | |
| Number of Participants With AEs Leading to Any Dose Reduction or Delays | GSK525762 60 mg+Enzalutamide 160 mg | Dose reduction | 10 | Participants | |
| Number of Participants With AEs Leading to Any Dose Reduction or Delays | GSK525762 60 mg Alternate+Enzalutamide 160 mg | Dose reduction | 7 | Participants | |
| Number of Participants With AEs Leading to Any Dose Reduction or Delays | GSK525762 60 mg+Abiraterone 1000 mg | Dose delay | 5 | Participants | |
| Number of Participants With AEs Leading to Any Dose Reduction or Delays | GSK525762 60 mg Alternate+Abiraterone 1000 mg | Dose delay | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03150056/results